Free Trial

Instil Bio (TIL) Competitors

Instil Bio logo
$36.56 -1.00 (-2.66%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$36.56 0.00 (0.00%)
As of 07:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TIL vs. AVBP, NTLA, CRON, REPL, IMTX, GYRE, DAWN, VIR, AVXL, and ABUS

Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include ArriVent BioPharma (AVBP), Intellia Therapeutics (NTLA), Cronos Group (CRON), Replimune Group (REPL), Immatics (IMTX), Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

Instil Bio vs. Its Competitors

Instil Bio (NASDAQ:TIL) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk.

Instil Bio has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

In the previous week, ArriVent BioPharma had 2 more articles in the media than Instil Bio. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Instil Bio. ArriVent BioPharma's average media sentiment score of 1.12 beat Instil Bio's score of 0.30 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Instil Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ArriVent BioPharma
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instil BioN/AN/A-$156.09M-$11.97-3.05
ArriVent BioPharmaN/AN/A-$69.33M-$3.77-6.18

Instil Bio's return on equity of -37.44% beat ArriVent BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Instil BioN/A -37.44% -25.08%
ArriVent BioPharma N/A -43.89%-29.67%

Instil Bio currently has a consensus price target of $119.00, suggesting a potential upside of 225.49%. ArriVent BioPharma has a consensus price target of $39.29, suggesting a potential upside of 68.75%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than ArriVent BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instil Bio
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
ArriVent BioPharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 47.2% of Instil Bio shares are owned by company insiders. Comparatively, 18.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Instil Bio received 81 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 95.83% of users gave ArriVent BioPharma an outperform vote while only 50.49% of users gave Instil Bio an outperform vote.

CompanyUnderperformOutperform
Instil BioOutperform Votes
104
50.49%
Underperform Votes
102
49.51%
ArriVent BioPharmaOutperform Votes
23
95.83%
Underperform Votes
1
4.17%

Summary

Instil Bio beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TIL vs. The Competition

MetricInstil BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$246.39M$3.09B$5.57B$8.63B
Dividend YieldN/A1.58%5.28%4.18%
P/E Ratio-3.1633.3227.1320.06
Price / SalesN/A469.84412.28157.10
Price / CashN/A168.6838.2534.64
Price / Book1.053.457.064.70
Net Income-$156.09M-$72.35M$3.23B$247.88M
7 Day Performance20.54%6.23%2.86%2.63%
1 Month Performance167.25%16.53%9.05%6.36%
1 Year Performance239.78%-16.90%31.39%14.05%

Instil Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TIL
Instil Bio
2.6702 of 5 stars
$36.56
-2.7%
$119.00
+225.5%
+237.3%$246.39MN/A-3.16410Short Interest ↑
High Trading Volume
AVBP
ArriVent BioPharma
1.4586 of 5 stars
$22.00
+3.5%
$39.29
+78.6%
+24.4%$752.69MN/A-5.8440Positive News
High Trading Volume
NTLA
Intellia Therapeutics
4.5892 of 5 stars
$7.16
+4.2%
$36.75
+413.3%
-64.8%$741.65M$45.57M-1.32600Analyst Revision
Gap Up
High Trading Volume
CRON
Cronos Group
1.9294 of 5 stars
$1.92
-3.0%
N/A-21.0%$739.98M$124.59M-14.77450Positive News
REPL
Replimune Group
4.509 of 5 stars
$9.57
+6.6%
$19.75
+106.4%
+8.7%$737.72MN/A-3.12210Positive News
High Trading Volume
IMTX
Immatics
2.6803 of 5 stars
$6.01
+11.5%
$14.67
+144.0%
-55.1%$730.52M$144.15M-9.11260Analyst Revision
Gap Up
High Trading Volume
GYRE
Gyre Therapeutics
0.367 of 5 stars
$7.68
-15.3%
N/A-21.8%$720.06M$100.64M384.0040Short Interest ↓
High Trading Volume
DAWN
Day One Biopharmaceuticals
1.7291 of 5 stars
$7.01
+9.9%
$30.57
+336.1%
-46.2%$710.55M$161.92M-6.8160
VIR
Vir Biotechnology
3.0685 of 5 stars
$5.07
+2.6%
$32.86
+548.1%
-50.6%$700.87M$14.30M-1.29580Positive News
AVXL
Anavex Life Sciences
3.9304 of 5 stars
$7.56
+0.4%
$44.00
+482.0%
+121.6%$645.41MN/A-13.7540Positive News
ABUS
Arbutus Biopharma
2.2499 of 5 stars
$3.36
flat
$5.50
+63.7%
+10.1%$643.53M$6.40M-7.8190Positive News

Related Companies and Tools


This page (NASDAQ:TIL) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners